PMID- 35975577
OWN - NLM
STAT- MEDLINE
DCOM- 20221121
LR  - 20221226
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 38
IP  - 11
DP  - 2022 Nov
TI  - Real-world utilization and outcomes of systemic therapy among patients with 
      advanced or recurrent endometrial cancer in the United States.
PG  - 1935-1945
LID - 10.1080/03007995.2022.2112872 [doi]
AB  - OBJECTIVE: Evaluate systemic therapy utilization patterns and outcomes by line of 
      therapy among patients with advanced/recurrent endometrial cancer (EC) treated in 
      the United States. METHODS: This retrospective observational study used the Optum 
      Clinformatics Extended Data Mart Date of Death database (1 January 2004-31 
      December 2019) and included de-identified data from adult patients with 
      advanced/recurrent EC who were treated with first-line (1L) platinum-based 
      chemotherapy and initiated second-line (2L) anti-neoplastic therapy. The index 
      date was the date of 1L therapy initiation. The number and sequence of treatments 
      received and the proportion of patients who received each type of treatment for 
      each line of therapy were evaluated. To account for new drug approvals, patients 
      first treated in 2018 or 2019 were also assessed separately. RESULTS: Among the 
      1317 patients who met all eligibility criteria, 520 (39.5%) and 235 (17.8%) 
      patients received 3 or 4+ lines of treatment, respectively, during a median total 
      follow-up time of 25.2 months (range, 2.5-173.3 months) following the index date. 
      Chemotherapy, including platinum- and non-platinum-based regimens, was the most 
      common treatment across all lines of therapy: 2L, 80.0%; 3L, 66.2%; 4L+, 80.4%. 
      Overall, 2.5%, 2.3%, and 8.9% of 2L, 3L, and 4L + patients, respectively, 
      received anti-program death 1 (anti-PD-1) immunotherapies. In patients first 
      treated in 2018 and 2019 (n = 163), 9.8% of patients received anti-PD-1 
      immunotherapy in the 2L. In the overall population, median time to next treatment 
      (TTNT) was 19.3, 10.5, and 8.1 months for patients undergoing 2L, 3L, and 4L 
      treatment, respectively. CONCLUSIONS: Among patients with advanced/recurrent EC 
      treated with 1L platinum-based therapy in clinical practice, chemotherapy was the 
      most common treatment choice across all lines of therapy. Immunotherapy use was 
      low overall but increased in patients who started treatment in 2018 or 2019. 
      Overall, median TTNT decreased as lines of therapy increased.
FAU - Liu, Jinan
AU  - Liu J
AD  - Value, Evidence, and Outcomes, GSK, Collegeville, PA, USA.
FAU - Emond, Bruno
AU  - Emond B
AD  - Analysis Group, Montreal, Quebec, Canada.
FAU - Maiese, Eric M
AU  - Maiese EM
AD  - Value, Evidence, and Outcomes, GlaxoSmithKline, Navy Yard, PA, USA.
FAU - Lafeuille, Marie-Helene
AU  - Lafeuille MH
AD  - Analysis Group, Montreal, Quebec, Canada.
FAU - Lefebvre, Patrick
AU  - Lefebvre P
AD  - Analysis Group, Montreal, Quebec, Canada.
FAU - Ghelerter, Isabelle
AU  - Ghelerter I
AD  - Analysis Group, Montreal, Quebec, Canada.
FAU - Wu, Caterina
AU  - Wu C
AD  - Analysis Group, Menlo Park, CA, USA.
FAU - Hurteau, Jean A
AU  - Hurteau JA
AD  - US Medical Affairs, Women's Oncology Portfolio, GSK, Waltham, MA, USA.
FAU - Thaker, Premal H
AU  - Thaker PH
AD  - Department of Gynecologic Oncology, Washington University School of Medicine, St. 
      Louis, MO, USA.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20220827
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
SB  - IM
MH  - Adult
MH  - Humans
MH  - United States
MH  - Female
MH  - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Neoplasm Recurrence, Local/drug therapy
MH  - Immunotherapy
MH  - Retrospective Studies
MH  - *Endometrial Neoplasms/drug therapy
OTO - NOTNLM
OT  - Endometrial cancer
OT  - immunotherapy
OT  - platinum-based chemotherapy
OT  - real-world evidence
OT  - treatment patterns
EDAT- 2022/08/18 06:00
MHDA- 2022/11/22 06:00
CRDT- 2022/08/17 04:03
PHST- 2022/08/18 06:00 [pubmed]
PHST- 2022/11/22 06:00 [medline]
PHST- 2022/08/17 04:03 [entrez]
AID - 10.1080/03007995.2022.2112872 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2022 Nov;38(11):1935-1945. doi: 10.1080/03007995.2022.2112872. 
      Epub 2022 Aug 27.